Comparison
Clomiphene vs Noopept
Side-by-side of Clomiphene and Noopept. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Clomiphene
Clomiphene citrate raises LH/FSH and endogenous testosterone in men. SERM TRT alternative, 25 to 50 mg, fertility preserved, visual side effects flagged.
Noopept
Noopept cognitive enhancer profile: 10 to 30 mg dosage, dipeptide nootropic mechanism, memory effects, and how it compares to piracetam.
Effects at a glance
Clomiphene
- •SERM that blocks estrogen-receptor negative feedback at the hypothalamus, raising LH and FSH
- •FDA approved 1967 for ovulation induction in anovulatory women at 50 to 100 mg cycle days 5 to 9
- •Off-label in men at 12.5 to 25 mg daily raises endogenous testosterone while preserving fertility
- •Enclomiphene (trans-isomer) is preferred for male use; cleaner PK and less estrogenic side effect burden
- •Visual disturbances occur in ~1 to 2% of users; persistent symptoms warrant immediate cessation
- •Letrozole has displaced clomiphene as first-line ovulation induction in PCOS (Legro 2014)
Noopept
- •Russian dipeptide nootropic developed in the 1990s, registered in Russia 2002 for cognitive impairment
- •Roughly 1,000-fold higher per-mg potency than piracetam; therapeutic dose 10 to 30 mg/day
- •Active metabolite cycloprolylglycine modulates AMPA receptors and increases NGF and BDNF in rodent hippocampus
- •Russian RCTs in stroke recovery and vascular cognitive impairment show modest improvements over 4 to 8 weeks
- •Western evidence base is essentially absent; healthy-adult enhancement trials have not been published
- •Unscheduled in the US but not approved for human consumption; UK is prescription-only since 2014
Side-by-side
| Attribute | Clomiphene | Noopept |
|---|---|---|
| Category | pharmaceutical | nootropic |
| Also known as | Clomid, clomiphene citrate, Serophene, enclomiphene | GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, Omberacetam |
| Half-life (hr) ↗ | 168 | 0.7 |
| Typical dose (mg) ↗ | 25 | 20 |
| Dosing frequency | 5-day pulse cycle days 5 to 9 (women); daily or every other day (men, off-label) | 2 to 3 times daily, last dose before mid-afternoon |
| Routes | oral | oral, sublingual |
| Onset (hr) | 6 | 0.5 |
| Peak (hr) | 7 | 1 |
| Molecular weight | 405.96 | 318.37 |
| Molecular formula | C26H28ClNO | C17H22N2O4 |
| Mechanism | Selective estrogen receptor modulator that antagonizes estrogen at the hypothalamus and pituitary, increasing GnRH and gonadotropin output, which drives gonadal steroidogenesis. | Hydrolyzed to active metabolite cycloprolylglycine; AMPA receptor modulation, BDNF and NGF upregulation, antioxidant and antiexcitotoxic effects. |
| Legal status | Prescription only (FDA approved for ovulation induction; off-label in men) | Approved in Russia and CIS states; prescription-only in UK; unscheduled and unapproved in US, EU varies |
| WADA status | banned | unknown |
| DEA / Rx | Rx only (not a controlled substance) | Not scheduled in the US |
| Pregnancy | Category X; contraindicated in pregnancy | Not recommended |
| CAS | 911-45-5 | 157115-85-0 |
| PubChem CID | 1548953 | 183503 |
| Wikidata | Q416785 | Q4321022 |
Safety profile
Clomiphene
Common side effects
- hot flushes
- mood changes
- abdominal discomfort
- breast tenderness
- visual disturbances (rare)
- headache
Contraindications
- pregnancy
- active liver disease
- ovarian cysts (not PCOS-related)
- uncontrolled thyroid or adrenal disorder
- abnormal uterine bleeding of undetermined origin
- hormone-sensitive cancer
Interactions
- tamoxifen: competing SERM activity; not used together(moderate)
- ospemifene: competing SERM activity(moderate)
- anastrozole: additive estrogen reduction; sometimes combined in male protocols(minor)
- TRT (exogenous testosterone): TRT suppresses HPT axis that clomiphene targets; do not combine(moderate)
Noopept
Common side effects
- headache
- irritability
- sleep disturbance with late-day dosing
- occasional blood pressure elevation
Contraindications
- pregnancy
- lactation
- pediatric use
- severe hepatic impairment
- severe renal impairment
Interactions
- memantine and other glutamatergic agents: theoretical AMPA-pathway interaction(minor)
- antidepressants: theoretical effect via BDNF axis, undocumented(minor)
- antihypertensives: occasional blood pressure elevation may require monitoring(minor)
Which Should You Take?
Clomiphene comes out ahead for most readers on the criteria we weight: 2 catalogued goals, prescription-only, oral dosing, with a Tier-A outcome catalogued. Noopept is the right call when one of the conditionals below applies.
- → If your priority is hormonal optimization, pick Clomiphene.
- → If your priority is fertility, pick Clomiphene.
- → If your priority is focus or working memory, pick Noopept.
- → If your priority is memory, pick Noopept.
Edge case: Clomiphene is contraindicated in pregnancy; Noopept is the safer pick if that applies.
Default choice: Clomiphene. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Noopept only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Clomiphene and Noopept?
Clomiphene and Noopept differ in category (pharmaceutical vs nootropic), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Clomiphene or Noopept?
Clomiphene half-life is 168 hours; Noopept half-life is 0.7 hours.
Can you stack Clomiphene with Noopept?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper